Notably, miR-141 and miR-330 have been shown to target OCT1, but the relevance of the modulation of these miRNAs to sorafenib resistance remains to be unveiled.61 Functional high-throughput approaches combined with analyses of human tissues have identified miR-1249 as a driver of the expansion of the CD133+ subpopulation that is responsible for primary and secondary resistance of CCA cells to cisplatin and gemcitabine.76 This evidence concerns the gene SLC22A1 and cholangiocarcinoma.